Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 12/20 | 0.45 |
| ▸ | ABL1 | P00519 | 3/20 | 0.34 |
| ▸ | BCR | P11274 | 3/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18627939 | 0.91 | SYK (0.47) | SYKABL1BCRCDK1CDK2 | |
| SCHEMBL18627956 | 0.87 | SYK (0.49) | SYKABL1BCRCDK1CDK2 | |
| SCHEMBL18627901 | 0.87 | SYK (0.49) | SYKABL1BCRCDK1CDK2 | |
| SCHEMBL18627914 | 0.87 | SYK (0.49) | SYKABL1BCRCDK1CDK2 | |
| SCHEMBL18627910 | 0.85 | SYK (0.47) | SYKABL1BCRCDK1CDK2 | |
| SCHEMBL18627951 | 0.85 | SYK (0.47) | SYKABL1BCRCDK1CDK2 | |
| SCHEMBL18627908 | 0.85 | SYK (0.47) | SYKABL1BCRCDK1CDK2 | |
| SCHEMBL18627916 | 0.81 | SYK (0.43) | SYKABL1BCRCDK2SMG1 | |
| SCHEMBL18627958 | 0.81 | SYK (0.47) | SYK | |
| SCHEMBL18640412 | 0.80 | SYK (0.44) | SYKCDK1CDK2SMG1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3350176-B1 | NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK | AB SCIENCE (FR) | 2021-04-28 | — | — | EP | claimed |
| US-10392373-B2 | Oxazole derivatives that inhibit Syk | AB SCIENCE (FR) | 2019-08-27 | — | — | US | claimed |
| US-20190055230-A1 | NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK | AB SCIENCE (FR) | 2019-02-21 | — | — | US | claimed |
| EP-3144307-A1 | NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK | AB Science (FR) | 2017-03-22 | — | — | EP | claimed |
| EP-3350176-B1 | NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK | AB SCIENCE (FR) | 2021-04-28 | — | — | EP | disclosed |
| EP-3350176-B1 | NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK | AB SCIENCE (FR) | 2021-04-28 | — | — | EP | disclosed |
| US-10392373-B2 | Oxazole derivatives that inhibit Syk | AB SCIENCE (FR) | 2019-08-27 | — | — | US | disclosed |
| US-10392373-B2 | Oxazole derivatives that inhibit Syk | AB SCIENCE (FR) | 2019-08-27 | — | — | US | disclosed |
| US-20190055230-A1 | NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK | AB SCIENCE (FR) | 2019-02-21 | — | — | US | disclosed |
| US-20190055230-A1 | NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK | AB SCIENCE (FR) | 2019-02-21 | — | — | US | disclosed |
| EP-3350176-A1 | NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK | AB Science (FR) | 2018-07-25 | — | — | EP | disclosed |
| WO-2017046302-A1 | NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK | AB SCIENCE (FR) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017046302-A1 | NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK | AB SCIENCE (FR) | 2017-03-23 | — | — | WO | disclosed |
| EP-3144307-A1 | NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK | AB Science (FR) | 2017-03-22 | — | — | EP | disclosed |
| EP-3144307-A1 | NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK | AB Science (FR) | 2017-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190055230-A1 | NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK | SYK, BTK, LCK | SYK 1/4885ABL1 203/4885BCR 246/4885 |
| US-10392373-B2 | Oxazole derivatives that inhibit Syk | SYK, BTK, LCK | SYK 1/4885ABL1 142/4885BCR 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.